Richmond continues preparations for full-cycle production of Sputnik V in Argentina
Date
4/26/2022 1:07:35 AM
(MENAFN- Trend News Agency)
Argentina's Richmond company continues to prepare for a
full-cycle production of the Russian Sputnik V vaccine, Trend reports citing
TASS .
Its source, commenting on the situation around the full-cycle
production of Sputnik V and other vaccines at the company's new
factory, said that the 'activity on technology transfer was not
suspended.' According to the source, the factory will launch
operations 'this October or November.'
The source said that the company is also considering producing
vaccines 'both from the US and from Europe and Asia' at the new
factory.
Before the new factory opens, Richmond may produce Sputnik V
from the active substance sent from Russia. According to the
newspaper, currently the company has suspended production because
the government is not sending new requests for Sputnik V. 'We have
1.4 mln doses of the vaccine stored and we can produce more when
asked,' the source said.
In early February, Argentine Health Minister Carla Vizzotti told
journalists that the country may receive the doses of Sputnik V
remaining under the contract with the Russian Direct Investment
Fund not from Russia but from Richmond. She said that Argentina
asked Russia not to send new batches since the country has enough
vaccines stored.
Sputnik V is the first vaccine against coronavirus that
Argentina obtained. On December 23, 2020, the country's regulator
issued a permit for the jab's emergency use and on December 29, the
republic began to inoculate its healthcare workers. Last June,
Richmond began local production with the use of the active
substance sent from Russia.
Tags:
MENAFN26042022000187011040ID1104092745
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.